Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Alessandro Prestipino; Alica Joana Emhardt; Konrad Aumann; David O’Sullivan; Sivahari Prasad Gorantla; Sandra Duquesne; Wolfgang Melchinger; Lukas M. Braun; Slavica Vučković; Melanie Boerries; Hauke Busch; Sebastian Halbach; Sandra Pennisi; Teresa Poggio; Petya Apostolova; Pia Veratti; Michael Hettich; Gabriele Niedermann; Mark Bartholomä; Khalid Shoumariyeh; Jonas S. Jutzi; Julius Wehrle; Christine Dierks; Heiko Becker; Annette Schmitt‐Graeff; Marie Follo; Dietmar Pfeifer; Jan Rohr; Sebastian Fuchs; Stephan Ehl; Frederike A. Hartl; Susana Minguet; Cornelius Miething; Florian H. Heidel; Nicolaus Kröger; Ioanna Triviai; Tilman Brummer; Jürgen Finke; Anna Lena Illert; Eliana Ruggiero; Chiara Bonini; Justus Duyster; Heike L. Pahl; Steven Lane; Geoffrey R. Hill; Bruce R. Blazar; Nikolas von Bubnoff; Erika L. Pearce; Robert Zeiser

doi:10.1126/scitranslmed.aam7729

Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Alessandro Prestipino(University of Freiburg), Alica Joana Emhardt(University Medical Center Freiburg), Konrad Aumann(University of Freiburg), David O’Sullivan(Max Planck Institute of Immunobiology and Epigenetics), Sivahari Prasad Gorantla(University Medical Center Freiburg), Sandra Duquesne(University Medical Center Freiburg), Wolfgang Melchinger(University Medical Center Freiburg), Lukas M. Braun(University Medical Center Freiburg), Slavica Vučković(The University of Queensland), Melanie Boerries(University of Freiburg), Hauke Busch(University of Freiburg), Sebastian Halbach(University of Freiburg), Sandra Pennisi(University of Freiburg), Teresa Poggio(University of Freiburg), Petya Apostolova(University of Freiburg), Pia Veratti(German Cancer Research Center), Michael Hettich(University of Freiburg), Gabriele Niedermann(University of Freiburg), Mark Bartholomä(University of Freiburg), Khalid Shoumariyeh(University Medical Center Freiburg), Jonas S. Jutzi(University of Freiburg), Julius Wehrle(University of Freiburg), Christine Dierks(University Medical Center Freiburg), Heiko Becker(University Medical Center Freiburg), Annette Schmitt‐Graeff(University of Freiburg), Marie Follo(University Medical Center Freiburg), Dietmar Pfeifer(University Medical Center Freiburg), Jan Rohr(University of Freiburg), Sebastian Fuchs(University of Freiburg), Stephan Ehl(University of Freiburg), Frederike A. Hartl(University of Freiburg), Susana Minguet(University of Freiburg), Cornelius Miething(German Cancer Research Center), Florian H. Heidel(Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)), Nicolaus Kröger(Universität Hamburg), Ioanna Triviai(Universität Hamburg), Tilman Brummer(University of Freiburg), Jürgen Finke(University Medical Center Freiburg), Anna Lena Illert(University Medical Center Freiburg), Eliana Ruggiero(Vita-Salute San Raffaele University), Chiara Bonini(Vita-Salute San Raffaele University), Justus Duyster(German Cancer Research Center), Heike L. Pahl(University Medical Center Freiburg), Steven Lane(The University of Queensland), Geoffrey R. Hill(The University of Queensland), Bruce R. Blazar(University of Minnesota), Nikolas von Bubnoff(German Cancer Research Center), Erika L. Pearce(Max Planck Institute of Immunobiology and Epigenetics), Robert Zeiser(University of Freiburg)

Science Translational Medicine

February 21, 2018

10.1126/scitranslmed.aam7729

Cited by 224

Abstract

-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.

Related Papers

No related papers found

Powered by citation graph analysis